▲ +9.30% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $180.25, with a high forecast of $208.00 and a low forecast of $145.00. The average price target represents a 9.30% upside from the last price of $164.92.
The current consensus among 12 polled investment analysts is to buy stock in Ascendis Pharma A/S. This Buy consensus rating has held steady for over two years.
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.